MA48051B1 - Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide - Google Patents

Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide

Info

Publication number
MA48051B1
MA48051B1 MA48051A MA48051A MA48051B1 MA 48051 B1 MA48051 B1 MA 48051B1 MA 48051 A MA48051 A MA 48051A MA 48051 A MA48051 A MA 48051A MA 48051 B1 MA48051 B1 MA 48051B1
Authority
MA
Morocco
Prior art keywords
indacen
hexahydro
sulfonamide
pyrazole
carbamoyl
Prior art date
Application number
MA48051A
Other languages
English (en)
Inventor
David Miller
Angus Macleod
Rio Gancedo Susana Del
Samuel Alexander Stratford
Original Assignee
Inflazome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazome Ltd filed Critical Inflazome Ltd
Publication of MA48051B1 publication Critical patent/MA48051B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un sel de sodium de n-((1,2,3,5,6,7-hexahydro-s-indacèn- 4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide et des hydrates, solvates et formes polymorphes de celui-ci. La présente invention concerne en outre des compositions pharmaceutiques comprenant ce composé, et l'utilisation de ce composé dans le traitement et la prévention de troubles médicaux et de maladies, plus particulièrement par inhibition de nlrp3.
MA48051A 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide MA48051B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1806578.9A GB201806578D0 (en) 2018-04-23 2018-04-23 Novel compound
PCT/EP2019/060311 WO2019206871A1 (fr) 2018-04-23 2019-04-23 Sel de sodium de n-((1,2,3,5,6,7-hexahydro-s-indacèn-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide

Publications (1)

Publication Number Publication Date
MA48051B1 true MA48051B1 (fr) 2020-08-31

Family

ID=62236309

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051082A MA51082A (fr) 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
MA48051A MA48051B1 (fr) 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA051082A MA51082A (fr) 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide

Country Status (28)

Country Link
US (2) US10973803B2 (fr)
EP (2) EP3606909B1 (fr)
JP (1) JP7382958B2 (fr)
KR (1) KR20210005589A (fr)
CN (1) CN112020495B (fr)
AR (1) AR114827A1 (fr)
AU (1) AU2019257973A1 (fr)
BR (1) BR112020021650A2 (fr)
CA (1) CA3097832A1 (fr)
CY (1) CY1123260T1 (fr)
DK (1) DK3606909T3 (fr)
ES (1) ES2811228T3 (fr)
GB (1) GB201806578D0 (fr)
HR (1) HRP20201263T1 (fr)
HU (1) HUE050369T2 (fr)
LT (1) LT3606909T (fr)
MA (2) MA51082A (fr)
MD (1) MD3606909T2 (fr)
ME (1) ME03822B (fr)
MX (1) MX2020011196A (fr)
PL (1) PL3606909T3 (fr)
PT (1) PT3606909T (fr)
RS (1) RS60646B1 (fr)
SI (1) SI3606909T1 (fr)
SM (1) SMT202000448T1 (fr)
TW (1) TW201943704A (fr)
UY (1) UY38186A (fr)
WO (1) WO2019206871A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3649112A1 (fr) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019034697A1 (fr) 2017-08-15 2019-02-21 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019034693A1 (fr) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019092171A1 (fr) 2017-11-09 2019-05-16 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759090A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
WO2019166619A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
WO2019166632A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
MX2021000660A (es) 2018-07-20 2021-03-25 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1.
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
EP4054563A1 (fr) * 2019-11-07 2022-09-14 Inflazome Limited Traitement et prévention d'une neuroinflammation ou d'un trouble encéphalique inflammatoire
JP2023501319A (ja) * 2019-11-07 2023-01-18 インフレイゾーム リミテッド 神経変性疾患の処置および予防
WO2021089781A1 (fr) * 2019-11-07 2021-05-14 Inflazome Limited Traitement ou prévention de troubles cérébraux psychiatriques faisant appel à l'inhibiteur de nlrp3 n-((1,2,3,4-hexahydro-s-indacène-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
JP2023501334A (ja) * 2019-11-07 2023-01-18 インフレイゾーム リミテッド 自己炎症性疾患の処置
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment
WO2021089776A1 (fr) * 2019-11-07 2021-05-14 Inflazome Limited Traitement et prévention d'un trouble cérébral traumatique
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
WO2022023907A1 (fr) 2020-07-31 2022-02-03 Novartis Ag Méthodes de sélection et de traitement de patients présentant un risque élevé d'événements cardiaques indésirables majeurs
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4802908A (en) * 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
BR0014003A (pt) * 1999-09-14 2002-05-21 Pfizer Prod Inc Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
TW201311693A (zh) * 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
JP6929792B2 (ja) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
EP3272739A1 (fr) 2016-07-20 2018-01-24 NodThera Limited Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes

Also Published As

Publication number Publication date
MA51082A (fr) 2021-05-19
HRP20201263T1 (hr) 2021-02-05
US10973803B2 (en) 2021-04-13
MD3606909T2 (ro) 2020-08-31
JP2021522195A (ja) 2021-08-30
GB201806578D0 (en) 2018-06-06
EP3606909A1 (fr) 2020-02-12
CN112020495B (zh) 2024-05-17
CY1123260T1 (el) 2021-12-31
HUE050369T2 (hu) 2020-11-30
US20210315862A1 (en) 2021-10-14
JP7382958B2 (ja) 2023-11-17
LT3606909T (lt) 2020-10-12
PT3606909T (pt) 2020-07-09
RS60646B1 (sr) 2020-09-30
AU2019257973A1 (en) 2020-11-19
EP3606909B1 (fr) 2020-05-27
UY38186A (es) 2019-11-29
ME03822B (fr) 2021-04-20
MX2020011196A (es) 2020-11-13
DK3606909T3 (da) 2020-08-24
EP3722281A1 (fr) 2020-10-14
CA3097832A1 (fr) 2019-10-31
SMT202000448T1 (it) 2020-09-10
PL3606909T3 (pl) 2020-11-16
SI3606909T1 (sl) 2020-09-30
AR114827A1 (es) 2020-10-21
CN112020495A (zh) 2020-12-01
TW201943704A (zh) 2019-11-16
WO2019206871A1 (fr) 2019-10-31
ES2811228T3 (es) 2021-03-11
US20200237723A1 (en) 2020-07-30
KR20210005589A (ko) 2021-01-14
BR112020021650A2 (pt) 2021-01-26

Similar Documents

Publication Publication Date Title
MX2020011196A (es) Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida.
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
SA521422143B1 (ar) 15-pgdh مثبط
MX2021004431A (es) Procesos novedosos.
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
MA47970B1 (fr) Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée
WO2020106647A3 (fr) Polythérapie comprenant un inhibiteur de krasg12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
MA44674A (fr) Inhibiteurs de bromodomaine
ATE368031T1 (de) Neue gamma secretase inhibitoren
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA34897B1 (fr) Formulations d'immunosupresseurs
MA53010B1 (fr) Formulations d'un inhibiteur de axl/mer
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
WO2019032528A8 (fr) Inhibiteurs bicycliques d'histone désacétylase
UA117046C2 (uk) [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ ПРОТОЗОЙНИХ ПРОТЕАСОМ ДЛЯ ЛІКУВАННЯ ПАРАЗИТАРНИХ ЗАХВОРЮВАНЬ, ТАКИХ ЯК ЛЕЙШМАНІОЗ
DE60006542D1 (de) Verbindungen die die tryptase-activität hemmen
MX2023015377A (es) Sal de potasio cristalina de 1-etil-n-((1,2,3,5,6,7-hexahidro-s-in dacen-4-il)carbamoil)piperidin-4-sulfonamida.
MA45002A (fr) Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
EA202190151A1 (ru) Фармацевтическая комбинация для применения при возрастных и/или дегенеративных заболеваниях